Patent · US Active

Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)

US10821183B2 · kind B2 · utility

0Cited by

85References

23Claims

0Family size

Assignee

Eagle Biologics, Inc. · US

Inventors

Alyssa M. Larson · Needham, US
Kevin Love · Somerville, US
Alisha K. Weight · Mill Creek, US
Alan Crane · Newton, US
Robert S. Langer · Newton, US
Alexander M. Klibanov · Boston, US

Key dates

Filing date	Nov 10, 2017
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Mar 6, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/54
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.